ADAPTIVE DEEP BRAIN STIMULATION FOR PARKINSON’S DISEASE: NEURAL BIOMARKERS, GAIT-SYNCHRONIZED CONTROL, AND PATIENT-SPECIFIC NETWORK NEUROMODULATION

Abstract

AbstractBackground.  Conventional  deep  brain  stimulation  provides  continuous  therapy  for Parkinson’s  disease,  but  fixed  stimulation  cannot  accommodate  medication  cycles,  sleep–wake transitions, gait freezing, dyskinesia, or biomarker drift. Adaptive deep brain stimulation offers closed- loop neuromodulation by adjusting stimulation according to sensed neural or behavioral signals.Materials and methods. A structured narrative review used randomized and nonrandomized trials,  prospective  cohorts,  documents,  neurophysiological  studies,  and  investigations  published through July 2026. Evidence was organized by biomarker validity, control architecture, programming feasibility, effectiveness, safety, energy efficiency, generalizability, and human-factor integration. A multicenter crossover study is proposed for adults with levodopa-responsive Parkinson’s disease and motor fluctuations despite optimized conventional stimulation.Results. Subthalamic beta amplitude and beta-burst duration remain the most mature control variables,  whereas  stimulation-entrained  gamma  activity,  cortical  signals,  wearable-derived  gait events, and multimodal decoders may better capture dyskinesia, freezing, and naturalistic behavior. Chronic studies suggest that personalized adaptive stimulation can improve residual motor symptoms and quality of life, while gait-synchronized and activity-dependent paradigms may address axial disability.  Major  limitations  include  sensing  artifacts,  unstable  biomarkers,  heterogeneous programming, small samples, insufficient blinding, and limited evidence regarding cognition, speech, falls, and device burden. The proposed primary endpoint combines blinded motor-state improvement with reduced troublesome dyskinesia and off time. Secondary endpoints include falls, gait freezing, speech, cognition, quality of life, stimulation energy, programming time, adverse events, calibration, and subgroup performance.Conclusion. Adaptive deep brain stimulation is transitioning from experimental physiology to regulated clinical therapy. Its durable value will depend on biomarker personalization, transparent algorithms, standardized outcomes, and independent multicenter validation.Keywords: Parkinson’s  disease,  adaptive  deep  brain  stimulation,  closed-loop neuromodulation,  beta  oscillations,  local  field  potentials,  gait  freezing,  neural  biomarkers, personalized neurostimulation.